Does Procapil block DHT without affecting hormones? What the evidence shows

Hormonal hair loss, also known as androgenetic alopecia, is a condition that affects both men and women. It involves progressive hair loss influenced by the activity of a hormone called dihydrotestosterone (DHT), derived from testosterone. There are treatments approved for this condition, such as finasteride, that reduce levels of this hormone, and many people ask about alternatives that don't directly alter the hormonal system. Procapil is one of the compounds that comes up in that conversation — a cosmetic ingredient complex that its supplier describes as acting on the enzyme that converts testosterone into DHT, at the scalp, without altering overall hormone levels.

Procapil is a patented active complex made up of three main ingredients: biotinyl tripeptide-1 (a peptide the supplier describes as strengthening hair anchorage), apigenin (a plant-derived flavonoid, described as supporting scalp circulation), and oleanolic acid (derived from olive leaves, reported in laboratory work to inhibit the enzyme 5-alpha reductase). That enzyme converts testosterone into DHT, which is what drives follicle miniaturisation in androgenetic alopecia.

The difference the supplier draws between Procapil and hormonal treatments like oral finasteride is route: Procapil is applied topically and is intended to act locally, rather than lowering hormone levels in the bloodstream. Topical finasteride also exists, but it remains a hormonal inhibitor and still lowers serum DHT to some degree depending on formulation, absorption, and frequency of use. Procapil is regulated as a cosmetic ingredient rather than a medicine, and it is not approved to treat hair loss anywhere. The proposed mechanism — that blocking the enzyme at the follicle reduces DHT formation only where it is needed — is a hypothesis supported by laboratory and animal work on its ingredients, not something demonstrated in the human scalp.

What the published human and laboratory evidence actually shows

The clearest human data comes from a 2024 study in the Journal of Cosmetic Dermatology by Samadi and colleagues, who assessed a topical formulation containing caffeine and Procapil 3% in men with male pattern hair loss and reported improvement and good tolerability. It is a short report on a small group, the formulation combined Procapil with caffeine, and it does not isolate Procapil's contribution — so it is a starting point, not proof of efficacy.

The manufacturer (Sederma) also publishes in-house testing of a Procapil lotion in male volunteers, reporting increases in anagen-phase hair. Different versions of that summary circulate with different doses, durations, application frequencies and percentages, and none of them appear in a peer-reviewed journal, so the specific figures are not reproduced here. Manufacturer funding, small samples and short durations are the standing limitations of the material available on this ingredient.

For the enzyme claim itself, the supporting work is preclinical. Laboratory studies report that oleanolic acid promotes proliferation in human hair matrix cells through beta-catenin signalling (Liu and colleagues, Fitoterapia, 2017), and that topical oleanolic acid promotes hair growth in mice, with the authors attributing the effect to regulation of inflammatory cytokines (Zhang and colleagues, Journal of Applied Biomedicine, 2023). Note what those studies show and do not show: neither one measured 5-alpha reductase inhibition in a human scalp, and in vitro and animal results don't always translate into clinical effects in people.

Apigenin is a natural compound found in plants such as parsley and chamomile. Laboratory studies have reported effects on skin cells and on circulation, and the supplier's rationale for including it rests on that work. We could not verify the specific keratinocyte-proliferation study previously cited here, so its description and reference have been removed; there is no direct hair-loss trial of apigenin to point to.

User Experiences

Community feedback on Procapil as a non-hormonal option reflects a mix of cautious optimism, skepticism, and scattered anecdotal success, especially among those seeking alternatives to DHT inhibitors like finasteride. Users on Tressless have discussed Procapil's proposed topical mechanism — local 5-alpha-reductase inhibition without systemic hormone changes — as its main appeal.

In a thread titled “Procapil - Has anyone heard of it?!”, users were initially unfamiliar with the compound but noted that it contains apigenin and oleanolic acid, which are believed to inhibit DHT and improve blood flow. However, responses were cautious, and there was a noticeable lack of long-term data or widespread community endorsements. Another post, “Why is Procapil not preferred?”, asked directly why the treatment hasn’t gained traction. Users replied that while it may have fewer side effects than minoxidil, it also lacks robust proof of efficacy in androgenetic alopecia compared to well-established treatments like finasteride or minoxidil.

One of the more supportive posts titled “Procapil is better than Minoxidil” generated a good number of upvotes. The user claimed superior results with Procapil and reported fewer side effects compared to minoxidil. This post spurred a conversation where users compared a range of topical products including RU58841, The Ordinary’s Multi Peptide Hair Serum, Redensyl, and Capixyl. RU58841 is an unapproved research chemical: it is not available as a medicine, has never completed human trials for hair loss, and its long-term safety is unknown. While some commenters were open to using Procapil, others emphasized that individual results vary and that minoxidil remains the default for most people.

In the post “Scalp care on Procapil and Procyanidin B2 hair serum,” a female user who had stopped using minoxidil due to allergies shared her switch to a Procapil-based Indian serum. She discussed how she paired it with coconut oil and sulfate-free shampoos, asking the community for recommendations on gentle scalp care. Other female users chimed in with suggestions for reducing irritation and maintaining hair health while on alternative serums.

A user shared a 2-month progress post combining 5% topical minoxidil and Procapil, reporting visible thickening and regrowth, particularly at the hairline. Though only one person shared visual results, it remains one of the few documented cases of perceived success with Procapil. On the more critical end, a post titled “How are Procapil, Capixl and Redensyl for combating hair loss?” drew direct comments calling these compounds ineffective, especially for androgenetic alopecia. One user insisted that despite good marketing, none of these alternatives could match finasteride or minoxidil in outcome.

Overall, community members generally say that while Procapil may appeal to people avoiding systemic hormone changes, user-reported efficacy is inconsistent. Most commenters treat it as something to add alongside other measures rather than a standalone therapy for moderate to severe androgenetic alopecia.

Apigenin and oleanolic acid: the key components

Apigenin's role in the complex is based on laboratory findings about skin cells and scalp circulation rather than on any hair-loss trial, as described above.

Oleanolic acid has been studied as a possible natural inhibitor of 5-alpha reductase, and is the ingredient the supplier's DHT argument rests on. The published work that we could verify is preclinical: the Fitoterapia 2017 organ-culture study on human hair matrix cells and beta-catenin, and the Journal of Applied Biomedicine 2023 mouse study in which topical oleanolic acid promoted hair growth on dorsal skin. Animal and cell-culture models limit direct human extrapolation, and the earlier claim here that oleanolic acid specifically inhibits "type I" 5-alpha reductase in people is not supported by a study we could confirm.

Where the evidence stands

The evidence on Procapil is preliminary. What exists is one small human study of a combination formula, unpublished manufacturer testing, and cell and animal work on the individual ingredients — with no large independent clinical trials. As a cosmetic topical, the side effects reported in the available material and by users are mostly mild scalp irritation, but the safety data are thin and come mainly from the manufacturer, so this is not the same as an established safety profile.

No direct comparative studies between Procapil and treatments like minoxidil or finasteride have been published, so no conclusion can be drawn about its relative efficacy. Its long-term effects beyond a few months also remain uninvestigated, which matters because androgenetic alopecia is a chronic condition.

If you are considering Procapil in place of, or alongside, an approved treatment, talk to a doctor or pharmacist before starting, stopping or combining anything — particularly with prescription drugs such as finasteride or dutasteride, and before using any unapproved research chemical. Finasteride and dutasteride are contraindicated in pregnancy and in women who may become pregnant, and broken or crushed tablets should not be handled by them.

References

Samadi, A., Rokhsat, E., Saffarian, Z., Moazzami Goudarzi, M., Kardeh, S., Nasrollahi, S. A., & Firooz, A. (2024). Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss. Journal of Cosmetic Dermatology, 23(4), 1492–1494. PMID 37990760. https://pubmed.ncbi.nlm.nih.gov/37990760/

Zhang, B., Zhang, W., Luo, J., He, J., et al. (2023). Effects of oleanolic acid on hair growth in mouse dorsal skin mediated via regulation of inflammatory cytokines. Journal of Applied Biomedicine, 21(1), 48–57. PMID 37016778. https://pubmed.ncbi.nlm.nih.gov/37016778/

Liu, B., Chen, X., Yi, H., et al. (2017). β-Catenin is involved in oleanolic acid-dependent promotion of proliferation in human hair matrix cells in an in vitro organ culture model. Fitoterapia, 121, 136–140. PMID 28723343. https://pubmed.ncbi.nlm.nih.gov/28723343/